Whalesbook
Achanak kya hua Emcure Pharma ke stock ke saath?
Dekho, Friday ko Emcure Pharma ka share seedha 2.3% neeche gir gaya, lagbhag ₹1,630 ke aas-paas trade kar raha tha. Interesting baat ye hai ki market general mein upar tha, matlab ye fall sirf company ke andar ki wajah se hua. Aur reason? Executive Director Namita Thapar.
Namita Thapar ki controversial remarks
Hua yun ki Namita Thapar ne social media par ek video mein Namaz ko exercise aur digestion ke liye faydemand bataya. Unka intention wellness commentary dene ka tha, par yeh video turant controversial ho gaya aur unhe kaafi trolling ka saamna karna pada. Baad mein unhone clarify kiya ki unhone Hindu practices ke baare mein bhi aise comments pehle share kiye hain, aur unhe lagta hai ki unke saath targeted criticism ho rahi hai.
Digital Zamane mein Leadership Risk
Aaj kal, companies aur unke senior leaders ko social media par kisi bhi statement ko lekar bahut careful rehna padta hai. Ek choti si baat bhi, chahe jo bhi intention ho, agar kisi sensitive topic (like religion) par ho, toh market mein badi gadbad kar sakti hai. Investors ab leaders ke public comments ko company ki stability aur judgment ka sign maan rahe hain, isiliye aisi cheezon se stock price mein turant giraavat aa jaati hai.
Valuation aur Purane Issues
Ab Emcure Pharma ki valuation ki baat karte hain. Iska Price-to-Earnings (P/E) ratio 35x se 50x ke beech hai, jo ki Dr. Reddy's Laboratories (17-18x) aur Cipla (21-22x) jaise rivals se kaafi zyada hai. Sun Pharmaceutical Industries ka P/E bhi iske aas-paas hi hai (36-37x), par leadership risk ko dekhte hue Emcure ka valuation thoda risky lag raha hai. Aur haan, company ka past bhi thoda saal pehle ke regulatory issues se bhara hai. Jaise 2016 mein U.S. Food and Drug Administration ne data integrity issues aur 'fraudulent' test data ke liye warning letter di thi. Aur 2022 mein HDT Bio Corp ne toh COVID-19 vaccine ke liye trade secrets chori karne ka aarop bhi lagaya tha. Ye sab cheezein investors ko hamesha alert rakhti hain.
Analysts Abhi bhi Positive hain
Par haan, itni gadbad ke baad bhi, analysts Emcure Pharma ko lekar positive hain. Cheh analysts ne consensus 'Strong Buy' rating di hai - jinmein se paanch 'Buy' keh rahe hain aur ek 'Hold' ka suggesion de raha hai. Average 12-month target price ₹1,795 se ₹1,830 ke beech hai, matlab current price se upar jaane ka potential hai. Analysts ka kehna hai ki Indian pharma sector robust chal raha hai, aur Q4 FY26 mein 10.5% ka growth dikhaaya hai. Toh overall sector acha hai, par leadership issues short-term mein stock ko hila sakte hain.